Connect Biopharmaceuticals Completes $55 Million Series B Financing to Accelerate Clinical Development of Novel Immune Modulators

from Venture Capital Access Online: Latest Venture Capital and Private Equity News http://bit.ly/2Vpxg5F
via IFTTT